Association Review
In brief The association between GABRA2 (Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2) and Epilepsy is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
11
Compounds
13
Trials
147 of 1,678 via GABRA2 compounds
Publications
0
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access 02
Provenance
Evidence and sources 1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access 2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access 11 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access 05
Population genetics
GWAS signals 3 GWAS phenotypes
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
Request access 06
Mechanism overlap
Shared mechanisms 1 shared pathway
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
Request access 07
Interventions
Therapeutics 13 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access 08
Human studies
Clinical trials 1,678 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access 09
Provenance
References & sources 9 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access 
